Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 471

Sort by

Sort Order Select

Journal Articles

Chidamide Combined with Decitabine Synergistically Induce Apoptosis of Acute Myeloid Leukemia By up-Regulating Perp gene In Vivo and in Vitro

Qing Li, MD, Yunfan Yang, MD, Yu Wu, MD

Blood (2019) 134 (Supplement_1): 536.

https://doi.org/10.1182/blood-2019-123876

Published: 2019

Journal Articles

Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication

Y. Lynn Lynn Wang, MD PhD, Carrie Franzen, PhD, Shengchun Wang, MD PhD, Girish Venkataraman, MD MBBS, Lei Li, MS, Nifang Niu, PhD, Madina Sukhanova, PhD, Yifan Tu, MD PhD, Juehua Gao, MD PhD, Yi-Hua Chen, MD, Shuo Ma, MD PhD, Richard A. Larson, MD, Lu Pin, MD PhD

Blood (2019) 134 (Supplement_1): 475.

https://doi.org/10.1182/blood-2019-125396

Published: 2019

Journal Articles

Ex Vivo Drug Sensitivity Screens Identify Personalized Treatment Options for CLL Patients

Sigrid Strand Skånland, PhD, Bendiksen Henrik, MSc, Andrea Cremaschi, PhD, Deepak Balaji Thimiri Govinda Raj, PhD, Ludvig Andre Munthe, MD PhD, Geir Erland Tjønnfjord, MD PhD, Kjetil Taskén, MD PhD

Blood (2019) 134 (Supplement_1): 5446.

https://doi.org/10.1182/blood-2019-121890

Published: 2019

Journal Articles

Efficacy and Toxicity of Lenalidomide for Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

Sravanthi Kotapati, MBBS, Insija Ilyas Selene, MBBS, Madeeha Shafqat, Syeda Fatima Hassan, MBBS, Zunairah Shah, MBBS, Arshia Akbar, MD, Owais ur Rehman, MBBS, Tariq Iqtidar Sadiq Syed, MD, Marium Ghani, MBBS, Syed Maaz Abdullah, MBBS, Maimoona Khan, MBBS, Jemin Aby Jose, MD, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5488.

https://doi.org/10.1182/blood-2019-129733

Published: 2019

Journal Articles

MCL-1 Inhibition By the Selective MCL-1 Inhibitor AMG-176 Induces in Vitro Activity Against Burkitt Lymphoma Cell Lines and Synergistically Enhances the Cytotoxic Effect of Chemotherapy and BH3 Mimetics

Tara Daly, BS, Thomas Ippolito, MSc, Juan J. Gu, MD PhD, Cory Mavis, MSc, Pallawi Torka, MD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD

Blood (2019) 134 (Supplement_1): 5303.

https://doi.org/10.1182/blood-2019-129052

Published: 2019

Journal Articles

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

Maimoona Khan, MBBS, Asma Waheed, MBBS, Rida Ul Jannat, MBBS, Arafat Ali Ali Farooqui, MD, Muhammad Saad Farooqi, MD, Ali Younas Khan, MD, Madeeha Shafqat, Muhaddis Ejaz Ahmad, MD, Muhammad Abdullah Yousaf, MBBS, MD, Tariq Iqtidar Sadiq Syed, MD, Syed Maaz Abdullah, MBBS, Sravanthi Kotapati, MBBS, Irbaz Riaz, MDMMSc, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5588.

https://doi.org/10.1182/blood-2019-128833

Published: 2019

Journal Articles

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Harish Kumar, PhD, Ujjal Kumar Mukherjee, PhD, Li Chen, PhD, Amit Kumar Mitra, PhD MSc, BSc

Blood (2019) 134 (Supplement_1): 5543.

https://doi.org/10.1182/blood-2019-131923

Published: 2019

Journal Articles

Advancements in Treatment for Newly Diagnosed Frail and Elderly Myeloma Patients: A Systematic Review

Syed Maaz Abdullah, MBBS, Tariq Iqtidar Sadiq Syed, MD, Muhammad Salman Faisal, MD MBBS, Awais Ijaz, MD, Syeda Sabeeka Batool, MBBS, MD, Muhaddis Ejaz Ahmad, MD, Muhammad Abdullah Yousaf, MBBS, MD, Saif Ur Rehman, MBBS, MD, Maaz Ahmed Yusufi, MD, Sravanthi Kotapati, MBBS, Maimoona Khan, MBBS, Asma Waheed, MBBS, Khadija Zia Zaidi, MBBS, Sikander Abdullah, MBBS, Faiz Anwer, MD

Blood (2019) 134 (Supplement_1): 5589.

https://doi.org/10.1182/blood-2019-128892

Published: 2019

Journal Articles

Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance

Rafael Renatino-Canevarolo, PhD, Praneeth Reddy Sudalagunta, PhD, Maria D Coelho Siqueira Silva, MSc, Mark B. Meads, PhD, Alexandre Tungesvik, MD, Gabriel De Avila, Alugubelli Raghunandan Reddy, Minerva Nong, Jamie Teer, PhD, Eric A. Welsh, PhD, Tint Lwin, MD PhD, Amit Kulkarni, PhD, Hongyue Dai, PhD, William S. Dalton, PhDMD, Kenneth H. Shain, MD PhD, Ariosto Siqueira Silva, PhD

Blood (2019) 134 (Supplement_1): 5544.

https://doi.org/10.1182/blood-2019-128442

Published: 2019

Journal Articles

Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center

Sabrina L Browning, MD, Terri L Parker, MD, Noffar Bar, MD, Stuart Seropian, MD, Alfred I Lee, MD PhD, Tara Anderson, PA, Natalia Neparidze, MD

Blood (2019) 134 (Supplement_1): 5569.

https://doi.org/10.1182/blood-2019-130134

Published: 2019

Journal Articles

Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients

Sarah R Brown, PhD MSc, BSc, Andrew Hall, Jessica Kendall, BSc, MSc, Emma Ingleson, Louise Flanagan, PhD, Holger W Auner, MD PhD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Mamta Garg, MD FRCP, FRCPath, Martin F. Kaiser

Blood (2019) 134 (Supplement_1): 5552.

https://doi.org/10.1182/blood-2019-123672

Published: 2019

Journal Articles

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

Michael A Spinner, Alexey Aleshin, MD MBA, Marianne A Santaguida, PhD, Steven A Schaffert, PhD, Taher Abbasi, MS, MBA, Jeffrey N Sanders, A Scott Patterson, MA, Diane Heiser, PhD, James L Zehnder, Peter L Greenberg, MD

Blood (2019) 134 (Supplement_1): 4239.

https://doi.org/10.1182/blood-2019-129473

Published: 2019

Journal Articles

Abnl Marro : An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes

Michael R. Savona, MD, Pierre Fenaux, MD PhD, Eric Padron, MD, Mrinal M Patnaik, MDMBBS, Uwe Platzbecker, MD, Adam Seegmiller, MD PhD, Raphael Itzykson, MD PhD, Guillermo F. Sanz, MD PhD, Valeria Santini, MD, Eric Solary, MD PhD

Blood (2019) 134 (Supplement_1): 4273.

https://doi.org/10.1182/blood-2019-130722

Published: 2019

Journal Articles

The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone

Jiri Minarik, MD PhD, Alexandra Jungova, Jan Straub, MD, Evzen Gregora, MD, Jana Bryknarova, Blanka Nemcova, Roman Hajek, MD

Blood (2019) 134 (Supplement_1): 5832.

https://doi.org/10.1182/blood-2019-130961

Published: 2019

Journal Articles

Implementation of a Cardio Oncology Protocol in Uruguay

Pía Oldan, MD, Andreina Gomez, MD, Gabriel Parma, MD, Cecilia Guillermo, MD, Lilián Díaz, MD, Matilde Boada, MD MSc

Blood (2019) 134 (Supplement_1): 5888.

https://doi.org/10.1182/blood-2019-127068

Published: 2019

Journal Articles

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

Lai N Chan, PhD, Mark A. Murakami, MDMA,MMSc, Rebecca Caesar, Christian Hurtz, PhD, Kohei Kume, PhD, Teresa Sadras, PhD, Seyedmehdi Shojaee, PhD, Petri Pölönen, MSc, Amol Ugale, PhD, Jaewoong Lee, PhD, Kadriye Nehir Cosgun, PhD, Huimin Geng, PhD, Merja Heinäniemi, PhD, Olli Lohi, MD PhD, Arun P. Wiita, MD PhD, Shai Izraeli, MD, David M Weinstock, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 3944.

https://doi.org/10.1182/blood-2019-130774

Published: 2019

Journal Articles

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Blood (2019) 134 (Supplement_1): 1269.

https://doi.org/10.1182/blood-2019-130996

Published: 2019

Journal Articles

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Zachary J Walker, BS, MS, Beau M Idler, BA, Michael J VanWyngarden, BS, Brett M. Stevens, PhD, Shelby C Bearrows, BS, Lorraine N Davis, BS, Andrew Hammes, MS, Clayton Smith, MD, Craig T Jordan, PhD, Tomer M Mark, MD MS, Peter A Forsberg, MD, Daniel W Sherbenou, MD PhD

Blood (2019) 134 (Supplement_1): 4404.

https://doi.org/10.1182/blood-2019-121937

Published: 2019

Journal Articles

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Cing Siang Hu, Fei Huang, Ronald Hoffman, MD, Xiaoli Wang, MD PhD

Blood (2019) 134 (Supplement_1): 2963.

https://doi.org/10.1182/blood-2019-126189

Published: 2019

Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD

Blood (2019) 134 (Supplement_1): 3052.

https://doi.org/10.1182/blood-2019-130807

Published: 2019

NARROW

Chidamide Combined with Decitabine Synergistically Induce Apoptosis of Acute Myeloid Leukemia By up-Regulating Perp gene In Vivo and in Vitro

Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication

Ex Vivo Drug Sensitivity Screens Identify Personalized Treatment Options for CLL Patients

Efficacy and Toxicity of Lenalidomide for Treatment of Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis

MCL-1 Inhibition By the Selective MCL-1 Inhibitor AMG-176 Induces in Vitro Activity Against Burkitt Lymphoma Cell Lines and Synergistically Enhances the Cytotoxic Effect of Chemotherapy and BH3 Mimetics

Carfilzomib Based Regimens for Treatment of Newly Diagnosed Multiple Myeloma: A Systematic Review

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Advancements in Treatment for Newly Diagnosed Frail and Elderly Myeloma Patients: A Systematic Review

Re-Constructing and Exploiting Transcriptional Regulatory Networks in Multiple Myeloma Drug Resistance

Daratumumab in the Clinic, a Real-Word Experience at Yale Cancer Center

Muktwelve: A Randomized Phase II Trial of Selinexor, Cyclophosphamide and Prednisolone Vs Cyclophosphamide and Prednisolone in Relapsed or Refractory Multiple Myeloma (RRMM) Patients

A Feasibility Study of Biologically Focused Therapy for Myelodysplastic Syndrome Patients Refractory to Hypomethylating Agents

Abnl Marro : An International Cooperative Trial for Patients with MDS/MPN Overlap Syndromes

The Role of Demographic and Social Factors on Decision Making in Patients with Relapsed and Refractory Multiple Myeloma Treated By Ixazomib, Lenalidomide and Dexamethasone

Implementation of a Cardio Oncology Protocol in Uruguay

Signaling Input from Divergent Pathways Subverts Malignant B-Cell Transformation

A Multi-Omic Precision Medicine Clinical Trial in Acute Leukemia

Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples

Combination Treatment with Imetelstat, a Telomerase Inhibitor, and Ruxolitinib Depletes Myelofibrosis Hematopoietic Stem Cells and Progenitor Cells

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only